Relay Therapeutics (RLAY) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Relay Therapeutics, Inc. ( RLAY ) 3rd Annual Guggenheim Healthcare Innovation Conference November 10, 2026 4:30 PM EST Company Participants Sanjiv Patel - CEO, President & Director Peter Rahmer - Chief Corporate Developm…

Phase 3 ReDiscover-2 trial in 2L breast cancer expected to complete enrollment in mid-2027 Updated data from ongoing Phase 1/2 ReInspire trial of zovegalisib in vascular anomalies to be featured in oral presentation at t…

CAMBRIDGE, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living …

CAMBRIDGE, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living …

Relay Therapeutics (NASDAQ: RLAY - Get Free Report) and BioMarin Pharmaceutical (NASDAQ: BMRN - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on…

Relay Therapeutics, Inc. (NASDAQ: RLAY - Get Free Report) CEO Sanjiv Patel sold 48,199 shares of Relay Therapeutics stock in a transaction dated Wednesday, October 7th. The stock was sold at an average price of $18.10, f…

Relay Therapeutics, Inc. (RLAY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript…

Squarepoint Ops LLC lessened its holdings in shares of Relay Therapeutics, Inc. (NASDAQ: RLAY) by 48.3% during a recent quarter, according to the company in its most recent disclosure with the SEC. The institutional inve…

VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in shares of Relay Therapeutics, Inc. (NASDAQ: RLAY) during a recent quarter, according to the company in its most recent Form 13F filing with the SEC. The institut…

Relay Therapeutics, Inc. (RLAY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks Transcript…

Allianz Asset Management GmbH acquired a new stake in Relay Therapeutics, Inc. (NASDAQ: RLAY) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquire…

Frazier Life Sciences Management L.P. acquired a new position in shares of Relay Therapeutics, Inc. (NASDAQ: RLAY) during a recent quarter, according to the company in its most recent filing with the Securities and Excha…

The sale had an approximate value of nearly $350,000. The transaction reduced the executive's direct equity position by 11%.…

CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living…

Bank of America Corp DE raised its stake in shares of Relay Therapeutics, Inc. (NASDAQ: RLAY) by 86.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The in…

RXRX, SDGR, RLAY and ABSI are using AI-powered platforms to transform drug discovery while advancing proprietary clinical pipelines.…
Kept in their own lane. A press release is the company talking, not reporting.
No upcoming events in the feeds.

